Table 2.

Treatment outcomes based on different body mass index before and after Solifenacin and estrogen intravaginal cream treatment.

	Normal weight 18.5 ≦ BMI<24 (n = 34)	Overweight 24 ≦ BMI<27 (n = 14)	Obese 27 ≦ BMI (n = 22 )	p
UDI-6
Pre-treatment	6.4 ± 3.6	8.9 ± 4.0	7.1 ± 3.7	0.056
Post-treatment	4.5 ± 3.6	6.1 ± 2.9	5.5 ± 4.3	0.639
Difference	− 2.1 ± 5.2	− 2.1 ± 4.2	− 1.5 ± 3.5	0.954
P (intergroup)	0.009	0.147	0.107
IIQ-7
Pre-treatment	6.8 ± 5.6	9.1 ± 5.4	8.0 ± 5.4	0.044
Post-treatment	5.5 ± 5.7	5.7 ± 3.7	6.1 ± 5.2	0.882
Difference	− 1.3 ± 5.7	− 3.3 ± 6.0	− 2.3 ± 5.0	0.362
P (intergroup)	0.923	0.358	0.193
OABSS
Pre-treatment	6.5 ± 3.5	9.5 ± 3.4	8.1 ± 3.4	0.004
Post-treatment	3.8 ± 2.2	7.7 ± 3.4	7.2 ± 3.1	0.247
Difference	− 2.7 ± 3.8	− 1.7 ± 4.6	− 1.1 ± 3.8	0.392
P (intergroup)	0.041	0.038	0.252
Micturition episodes
Pre-treatment	10.1 ± 3.8	9.0 ± 4.1	8.3 ± 2.5	0.247
Post-treatment	7.8 ± 3.8	7.9 ± 3.8	7.4 ± 3.4	0.439
Difference	− 2.4 ± 3.4	− 1.2 ± 4.2	− 0.4 ± 3.2	0.501
P (intergroup)	0.008	0.195	0.646
Nocturia episodes
Pre-treatment	2.8 ± 1.7	3.2 ± 2.1	2.7 ± 2.1	0.979
Post-treatment	1.8 ± 1.5	2.5 ± 1.2	2.6 ± 0.9	0.172
Difference	− 0.8 ± 1.3	− 0.7 ± 0.8	0.5 ± 1.5	0.026
P (intergroup)	0.021	0.096	0.235
Urgency episodes
Pre-treatment	3.5 ± 3.2	4.6 ± 4.7	3.0 ± 2.6	0.041
Post-treatment	2.7 ± 2.8	4.0 ± 4.9	2.3 ± 2.1	0.424
Difference	− 0.6 ± 4.9	− 1.8 ± 7.7	− 1.2 ± 3.0	0.407
P (intergroup)	0.606	0.708	0.166
Urinary incontinence episodes
Pre-treatment	0.7 ± 1.0	2.7 ± 2.2	1.9 ± 1.5	< 0.001
Post-treatment	1.2 ± 1.2	2.0 ± 2.2	1.0 ± 1.3	0.234
Difference	0.6 ± 0.8	− 0.7 ± 3.9	− 0.9 ± 2.0	0.143
P (intergroup)	0.008	0.632	0.094

Data are presented as mean ± standard deviation or as number (percent) of patients.

UDI-6: the short form of the Urogenital Distress Inventory, IIQ-7: the short form of the Incontinence Impact Questionnaire, OABSS: overactive bladder symptom score.